Dyne Therapeutics‘s patent involves complexes with muscle-targeting agents linked to molecular payloads, inhibiting DUX4 expression. Claim 1 specifies an anti-transferrin receptor antibody linked to an oligonucleotide targeting a specific region of human transferrin receptor protein 1. The oligonucleotide includes modifications and a region complementary to a specific nucleotide sequence. GlobalData’s report on Dyne Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dyne Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Dyne Therapeutics's grant share as of May 2024 was 2%. Grant share is based on the ratio of number of grants to total number of patents.
Complex of anti-transferrin receptor antibody linked to oligonucleotide
A recently granted patent (Publication Number: US12012460B2) discloses a complex comprising an anti-transferrin receptor antibody covalently linked to an oligonucleotide. The antibody binds to a specific region of the human transferrin receptor protein 1 (TfR1) and the oligonucleotide contains modifications and a region of complementarity to a specific nucleotide sequence. The modifications include 2'-modified nucleosides and a modified backbone, and the oligonucleotide ranges from 15-30 nucleotides in length. Additionally, the complex can be obtained through a cycloaddition reaction involving specific linkers and sugar molecules can be part of the antibody structure.
Furthermore, the patent claims cover variations in the length of the region of complementarity, the type of oligonucleotide used (such as phosphorodiamidate morpholino oligomer), and the specific antibodies involved (such as ScFv, Fab fragment). The complex is designed for targeting genes associated with diseases related to muscle weakness, including muscular dystrophy, by binding to specific regions of the transferrin receptor protein. The patent also details the use of cleavable linkers and specific sequences for the covalent linkage between the antibody and the oligonucleotide, providing a novel approach for therapeutic interventions targeting muscle-related disorders.
To know more about GlobalData’s detailed insights on Dyne Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
